STAT+: The biotech scorecard for the second quarter: 24 stock-moving events to watch
Here is STAT’s biotech scorecard for the second quarter. Plus, a rundown of FDA-sponsor meetings that could be a clue to changes under Trump.
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter.
New this quarter, we’re tracking a select number of Food and Drug Administration-drug sponsor meetings as a potential signal that agency operations are being impacted by changes made by the Trump administration.
Vera Therapeutics: Top-line results from the atacicept Phase 3 ORIGIN trial in IgA nephropathy.
